Atlas Datasets
HTA data is currently organized by the original publication. Our goal is to incorporate these data into multi-functional Atlases. Over time search and other means of accessing data will be added.
Featured Publications
The spatial landscape of progression and immunoediting in primary melanoma at single cell resolution.
Nirmal, A.J., Maliga, Z., Vallius, T., Quattrochi, B., Chen, A.C., Jacobson, C.A., Pelletier, R.J., ... Lian, C.G., Murphy, G.F., Santagata, S., Sorger, P.K. (2022)
Cancer Discovery, 12(6), 1518–1541. https://doi.org/10.1158/2159-8290.CD-21-1357
Multiplexed 3D atlas of state transitions and immune interactions in colorectal cancer.
Lin, J.-R., Wang, S., Coy, S., Tyler, M., Yapp, C., Chen, Y.-A., Heiser, C.N., Lau, K.S., Santagata, S., Sorger, P.K. (2021).
Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer.
Mehta, A.K., Cheney, E.M., Hartl, C.A., Pantelidou, C., Oliwa, M., Castrillon, J.A., Lin, Lin, J.-R., ... Guerriero, J. (2021).
Nature Cancer, 2(1), 66–82. https://doi.org/10.1038/s43018-020-00148-7
Temporal and spatial topography of cell proliferation in cancer.
Gaglia, G., Kabraji, S., Angyropoulu, D., Dai, Y., Wang, S., Bergholz, J., Coy, S., Lin, J.-R., ... Santagata, P. (2022).
Nature Cell Biology, 24(3), 316-326 https://doi.org/10.1038/s41556-022-00860-9
Methods and software
Qualifying antibodies for image-based immune profiling and multiplexed tissue imaging.
Du, Z., Lin, J.-R., Rashid, R., Maliga, Z., Wang, S., Aster, J. C., Izar, B., Sorger, P. K., & Santagata, S. (2019).
Nature Protocols, 14(10), 2900–2930. https://doi.org/10.1038/s41596-019-0206-y
Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-cycif and conventional optical microscopes.
Lin, J.-R., Izar, B., Wang, S., Yapp, C., Mei S., Shah, P.M., Santagata, S., & Sorger, P.K. (2018).
ELife, 7. https://doi.org/10.7554/eLife.31657
Profiling and Atlasing
Spatial intra-tumor heterogeneity is associated with survival of lung adenocarcinoma patients.
Wu, H.-J., Temko, D., Maliga, M., Moreira. A., Sei, E., Conterno Minussi, D., Dean, J., Lee, C. Xu, Q., ... Michor, F. (2022).
Cell Genomics, 2(8), 100165. https://doi.org/10.1016/j.xgen.2022.100165
Evolution of delayed resistance to immunotherapy in a melanoma responder.
Liu, D., Lin, J.-R., Robitschek, E.J., Kasumova, G.G., Heyde, A., Shi, A., Kraya, A., ... Boland, G.M. (2021).
Nature Medicine, 27, 985–992. https://doi.org/10.1038/s41591-021-01331-8
Clinical efficacy and molecular response correlates of the WEE1 inhibitor adavosertib combined with cisplatin in patients with metastatic triple-negative breast cancer.
Keenan, T.E., Li, T., Vallius, T., Guerriero, J.L., Tayob, N., Kochupurakkal, B., Davis, J., Pastorello, R., ... Tolaney, S.M. (2021).
Clinical Cancer Research, 2(1), 66-82. https://doi.org/10.1158/1078-0432.CCR-20-3089